Chairman of the Board of SK-Pharmaceuticals LLP Erken Zhakatay met with the director of the pharmaceutical department of Sinopharm International, Luna Xue, and the executive director of the Antigen Research and Production Enterprise, Zhanat Abdraimova.
The meeting was dedicated to issues of bilateral cooperation.
During the meeting, Luna Xue explained that Sinopharm International is a Chinese international corporation and a wholly owned subsidiary of Sinopharm.
The company is actively involved in the global pharmaceutical market, has overseas networks and spans five continents.
Sinopharm International has built close cooperative relationships with more than 100 world-renowned suppliers of drugs, medical equipment and health products.
In turn, the executive director of the Antigen Research and Production Enterprise noted that a project for the production of vaccines and immunobiological drugs is being developed together with Sinopharm.
NPP Antigen is one of the largest manufacturers of immunobiological veterinary drugs and diagnostic tests in Central Asia and Kazakhstan.
In 2021, the company built a new production site with a full cycle of production of parenteral drugs for liquid and lyophilized powders, where the inactivated vaccine “QazCovid-in®” was produced.
In addition, NPP Antigen participates in a consortium agreement with Nazarbayev University for the development of anticancer drugs.
Today, the company is working on the development of new medicines, and a representative of Antigen announced its intention to cooperate with the Unified Distributor as part of concluding a long-term agreement.
As a result of the meeting, the Unified Distributor expressed interest in further cooperation on this issue.
.png)
.png)
.jpeg)